Occam’s UK Biotech Practice Accelerates with Placement of CSO at Nucleome

Occam’s traction in the UK biotech market continues to grow with the placement of Steve Harrison, an accomplished global entrepreneurial drug hunter, as CSO of Nucleome Therapeutics, an Oxford spin out and M Ventures/J&J Innovation/Pfizer Ventures/OSE/British Patient Capital investment exploring the dark genome for therapeutic opportunities.

Harrison has three decades of experience in the biotechnology sector, with leadership experience at product-driven research organizations at all stages, from target identification to new drug registration and clinical development in multiple therapeutic areas, including immunotherapeutics, oncology, rare diseases, and pain management.

Prior to Nucleome, Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area, most recently as Chief Scientific Officer of Engine Biosciences.  Previous roles include Chief Scientific Officer and Senior Vice President at Relypsa (divested to Galencia for $1.53 billion in 2016).